HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight
April 24, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the...
EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight
April 22, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 22, 2024 (GLOBE NEWSWIRE) -- EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the...
HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche
April 17, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 17, 2024 (GLOBE NEWSWIRE) -- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen...
TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio, BioNTech, BiOneCure Therapeutics
April 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck,...
XORTX Welcomes New Member to the Board of Directors
April 08, 2024 07:30 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical...
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
April 04, 2024 07:05 ET
|
NextCure
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
April 01, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain
March 21, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, March 21, 2024 (GLOBE NEWSWIRE) -- PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the...
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
March 19, 2024 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Global Influenza Vaccine Market to Attain Valuation of USD 22.71 Billion By 2032: Astute Analytica
March 05, 2024 08:30 ET
|
AstuteAnalytica India Pvt. Ltd.
New Delhi, March 05, 2024 (GLOBE NEWSWIRE) -- Global influenza vaccine market is projected to hit the market valuation of US$ 22.71 billion by 2032 from US$ 8.78 billion in 2023 at a CAGR of 11.07%...